Iqirvo Coupons & Savings Card – Discount Prices from $12196.22
My prescription
Edit
80MG, Iqirvo (30 Tablets)
Select pharmacy

Albertsons
$12196.22
COUPON PRICE
Walgreens
$12384.82
COUPON PRICE
Walmart
$12484.38
COUPON PRICEIqirvo savings card
Show this card to your pharmacist
Albertsons
$12196.22
BIN
ID
PCN
GRP
015995
LHKPV552212
GDC
DR33
Powered by
Price history for Iqirvo
30 Tablets, 80MG
Average retail price for Iqirvo
Average SaveHealth price for Iqirvo
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Iqirvo dosage forms
Dosage Quantity Price from Per unit 80MG 30 Tablets $12484.38 $416.15
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 80MG | 30 Tablets | $12484.38 | $416.15 |
What is Iqirvo used for?
Iqirvo is used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
How much does Iqirvo cost?
The cost of Iqirvo can vary depending on factors such as the pharmacy, location, insurance coverage, and any available discounts or patient assistance programs. It is recommended to check with local pharmacies or consult with a healthcare provider for the most accurate and up-to-date pricing information.
What is the difference between Iqirvo and Livdelzi?
Iqirvo and Livdelzi are both medications used to treat specific conditions, but they differ in their active ingredients and the conditions they are designed to treat. Iqirvo contains the active ingredient bimekizumab and is used primarily for the treatment of moderate to severe plaque psoriasis. Livdelzi, on the other hand, contains the active ingredient deucravacitinib and is also used for treating moderate to severe plaque psoriasis. The main difference lies in their mechanisms of action; bimekizumab is a monoclonal antibody that targets interleukin-17A and interleukin-17F, while deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor. This difference in action may influence the choice of treatment based on patient-specific factors and physician recommendations.
